NasdaqGS:HALOBiotechs
Halozyme Therapeutics (HALO) Lands Incyte Deal On A Valuation That Still Looks Undervalued
Halozyme Therapeutics (HALO) drew fresh attention after signing a global partnership and licence agreement with Incyte to apply its Enhanze technology to subcutaneous formulations of INCA033989 for mutCALR myeloproliferative neoplasms.
See our latest analysis for Halozyme Therapeutics.
Halozyme Therapeutics has also been in focus for its share price performance, with a 30 day share price return of 12.46% and a 1 year total shareholder return of 37.86% pointing to building momentum around the...